Compound: bifonazole
SMILES: n1cn(C(c2ccc(-c3ccccc3)cc2)c4ccccc4)cc1
InChIKey: OCAPBUJLXMYKEJ-UHFFFAOYSA-N
Synonyms: bifonazole, 60628-96-8, Mycospor, Trifonazole, Bifonazol, BAY H 4502, Bifonazolum, 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole, 1-(alpha-(4-Biphenylyl)benzyl)imidazole, Bay-h-4502, Bay H-4502, (+-)-1-(p,alpha-Diphenylbenzyl)imidazole, DTXSID9045631, NSC-758954, QYJ305Z91O, D01AC10, DTXCID7025631, 1-((4-biphenylyl)-phenylmethyl)-1H-imidazole, 1H-Imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-, (+-)-, 1-(phenyl(4-phenylphenyl)methyl)-1H-imidazole, 1-[phenyl(4-phenylphenyl)methyl]-1H-imidazole, bifonazolo, RefChem:568329, CHEBI:31286, 1-((RS)-(Biphenyl-4-yl)(phenyl)methyl)-1H-imidazole, 262-336-6, Amycor, Azolmen, 1-[phenyl-(4-phenylphenyl)methyl]imidazole, Bifonazol [INN-Spanish], Bifonazolum [INN-Latin], 1H-Imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)-, 1-([1,1'-Biphenyl]-4-yl(phenyl)methyl)-1H-imidazole, (+/-)-Bifonazole, 1-(p,alpha-Diphenylbenzyl)imidazole, MFCD00865567, MLS000028576, CHEMBL277535, 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole, 1H-Imidazole, 1-((1,1'-biphenyl)-4-ylphenylmethyl)-, (+-)1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole, NCGC00018254-03, SMR000058970, 1-[biphenyl-4-yl(phenyl)methyl]imidazole, 1-(ALPHA,4-DIPHENYLBENZYL)IMIDAZOLE, 1-({[1,1'-biphenyl]-4-yl}(phenyl)methyl)-1H-imidazole, Mycospor (TN), CAS-60628-96-8, SR-01000003136, EINECS 262-336-6, BRN 0618427, 1-[([1,1'-Biphenyl]-4-yl)(phenyl)methyl]-1H-imidazole, UNII-QYJ305Z91O, Mycosporan, Bedriol, Mycosporan;, Bifazole;, Mycospor;, Bifonazole CRS, Bifonazole [USAN:INN:BAN:JAN], Bifonazole (Standard), CPD000058970, BIFONAZOLE [MI], BIFONAZOLE [INN], BIFONAZOLE [JAN], 1-[PHENYL-(4-PHENYLPHENYL)-METHYL]IMIDAZOLE, Opera_ID_1656, Spectrum2_000035, Spectrum3_001970, (.+/-.)-Bifonazole, BIFONAZOLE [USAN], Imidazole, 1-(alpha-(4-biphenylyl)benzyl)-, 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole, BIFONAZOLE [MART.], cid_2378, BIFONAZOLE [WHO-DD], SCHEMBL36803, BSPBio_003570, 5-23-04-00292 (Beilstein Handbook Reference), MLS000759537, MLS001074074, MLS001424050, SPECTRUM1505309, SPBio_000129, Bifonazole - Bio-X trade mark, orb1309472, orb3139347, Bifonazole (JP18/USAN/INN), BIFONAZOLE [EP IMPURITY], Bifonazole, >=98% (HPLC), Bifonazole for system suitability, CHEBI:78692, HY-B0301R, KBio3_002922, 1-(p,?-Diphenylbenzyl)imidazole, BIFONAZOLE [EP MONOGRAPH], GLXC-01551, HMS1922B18, HMS2051F04, HMS2090K13, HMS2093B09, HMS2232J24, HMS3374H02, HMS3393F04, HMS3651G21, HMS3715L21, HMS5080M15, Pharmakon1600-01505309, HY-B0301, MSK10152, Tox21_110850, BDBM50128548, CCG-39996, DL-338, EBC-01060, NSC758954, s1854, STK618771, Bifonazole for system suitability CRS, AKOS005553008, Tox21_110850_1, AB07497, CCG-100993, DB04794, FP36903, KS-5111, NC00243, NSC 758954, [phenyl(4-phenylphenyl)methyl]imidazole, MRF-0000274, NCGC00018254-02, NCGC00018254-04, NCGC00018254-05, NCGC00018254-08, NCGC00018254-09, NCGC00089815-02, NCGC00089815-03, NCGC00089815-04, AC-15414, BP164253, DA-51112, SY052768, SBI-0206755.P001, 1-(.alpha.-(4-Biphenylyl)benzyl)imidazole, 1-[alpha-(4-biphenylyl)-benzyl]-imidazole, (Biphenyl-4-yl)-imidazol-1-yl-phenylmethane, B4173, NS00003619, ST50993921, SW197623-3, 1-[4-Biphenylyl(phenyl)methyl]-1H-imidazole, VU0239694-7, D01775, EN300-295624, Imidazole, 1-(.alpha.-(4-biphenylyl)benzyl)-, AB00383029-16, AB00383029_17, AB00383029_18, (.+/-.)-1-(p,.alpha.-Diphenylbenzyl)imidazole, Q421162, 1-(1-Biphenyl-4-yl-2-phenyl-methyl)-1H-imidazole, SR-01000003136-4, SR-01000003136-6, (+/-)-1-(P,.ALPHA.-DIPHENYLBENZYL)IMIDAZOLE, BRD-A94543220-001-02-3, BRD-A94543220-001-12-2, BRD-A94543220-001-23-9, BRD-A94543220-001-24-7, Z275375166, 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole (bifonazole), 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole( Bifanozole), 1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole(Bifonazole), 1-[[1,1'-Biphenyl]-4-yl(phenyl)methyl]-1H-imidazole #, Bifonazole, European Pharmacopoeia (EP) Reference Standard, 1H-Imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)-, (.+/-.)-, 1H-IMIDAZOLE, 1-((1,1'-BIPHENYL)-4-YLPHENYLMETHYL)-, (+/-)-, Bifonazole, Pharmaceutical Secondary Standard; Certified Reference Material, Bifonazole for system suitability, European Pharmacopoeia (EP) Reference Standard
Theoretical properties:
molecular_formula: C22H18N2
molecular_weight: 310.4 g/mol
exact_mass: 310.146998583 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 1
rotatable_bond_count: 4
heavy_atom_count: 24
topological_polar_surface_area: 17.8 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 2.45e-03 g/L
Descriptions:
pubchem: 1-[biphenyl-4-yl(phenyl)methyl]imidazole is a member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1. It is a member of biphenyls and a member of imidazoles.
chebi: A member of the class of imidazoles carrying an α-(biphenyl-4-yl)benzyl substituent at position 1.
chembl: BIFONAZOLE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Bifonazole (trade name Canespor among others) is an imidazole antifungal drug used in form of ointments.
It was patented in 1974 and approved for medical use in 1983. There are also combinations with carbamide for the treatment of onychomycosis.